Cyclopeptide Utilizing Patents (Class 514/21.1)
  • Patent number: 11325905
    Abstract: There is described herein imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 10, 2022
    Assignee: The Governors of the University of Alberta
    Inventors: Dennis Hall, Michael Weinfeld, Sylvain Bernard, Tristan Verdelet, Timothy Morgan, Vikie Lamontagne, Zahra Shire, Afsaneh Lavasanifar
  • Patent number: 11274126
    Abstract: The present subject matter provides pH triggered peptides, as well as compositions methods, devices, and systems comprising the same. The pH triggered peptides include cyclic and short linear peptides, and may have higher affinity to a membrane lipid bilayer at low pH than at neutral or high pH.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: March 15, 2022
    Assignee: University of Rhode Island Board of Trustees
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Keykavous Parang
  • Patent number: 11246961
    Abstract: The present invention provides scaffolds that include a polymer and a cyclic peptide ligand. The peptide ligand increases the attachment of endothelial cells and/or progenitor cells to the scaffold. The present invention also provides engineered tissues that include the provided scaffolds. The present invention also provides coatings that include a coating polymer and a cyclic peptide ligand. The present invention also provides methods of improving endothelialization and vascularization of endothelial cells and/or progenitor cells for tissue regeneration in a subject and of repairing bone defects in a subject, by implanting a provided scaffold.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: February 15, 2022
    Assignee: The Regents of the University of California
    Inventors: Aijun Wang, Kit Lam
  • Patent number: 11096953
    Abstract: Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: August 24, 2021
    Assignee: BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Joseph Desimone, Yogen Saunthararajah
  • Patent number: 11026940
    Abstract: The invention provides compositions that increase the mobilization, homing, expansion, and/or differentiation of stem cells and methods of using the same for the treatment of mammals.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: June 8, 2021
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, Greg Thomas
  • Patent number: 11021518
    Abstract: Novel peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating infection and/or sepsis. These analogs are active at concentrations below those needed to provide a bactericidal or bacteriostatic effect, and function by initially recruiting effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response characteristic of sepsis and septic shock. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensin.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: June 1, 2021
    Assignee: The University of Southern California
    Inventors: Michael E. Selsted, Dat Q. Tran, Justin B. Schaal
  • Patent number: 10947591
    Abstract: The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: March 16, 2021
    Assignee: Genentech, Inc.
    Inventors: Brian Yaspan, Robert Royal Graham, Amy Dressen, Zhengrong Li, Erich Strauss, Teodorica Bugawan
  • Patent number: 10905744
    Abstract: The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide drugs with advantageously high bioavailability, safety and costeffectiveness. In particular, the invention provides a peptide drug having a molecular weight of equal to or less than 5 kDa for use as a medicament, wherein said peptide drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex, and with a pharmaceutically acceptable complexing agent. The invention also provides a pharmaceutical composition comprising: a peptide drug having a molecular weight of equal to or less than 5 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex; and a pharmaceutically acceptable complexing agent.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: February 2, 2021
    Assignee: CYPRUMED GMBH
    Inventors: Florian Föger, Martin Werle
  • Patent number: 10889620
    Abstract: Solid state forms of Linaclotide, processes for their preparation, compositions comprising them and medical uses thereof are provided. The solid state forms of Linaclotide are useful in the preparation of other solid state forms of Linaclotide, particularly the amorphous form.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: January 12, 2021
    Assignee: NOVETIDE LTD.
    Inventors: Chaim Eidelman, Hagi Alon, Dov Vayer, Sharon Penias-Navon, Jonathan Enav
  • Patent number: 10851134
    Abstract: A method for preparing a cyclopeptide, which includes the following steps: (A) providing compounds represented by the following formulas (II-1) or (II?-1) and (II-2); (B) performing a reaction between the compounds of formulas (II-1) or (II?-1) and (II-2), to obtain a compound represented by the following formula (II-3) and (II?-3), respectively; (C) performing a reaction between the compound of formula (II-3) or (II?-3) and a compound represented by the following formula (II-4) or (II?-4), respectively, is performed, to obtain a compound represented by the following formula (II-5), and (II?-5), respectively; (D) performing a cyclization reaction of the compound of formula (II-5) or (II?-5) with a catalyst of formula (III), to obtain a compound represented by the following formula (I) or (I?), respectively. The formulas (I), (I?), (II-1) to (II-5), (II?-1) to (II?-5) and (III) are shown in the specification.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: December 1, 2020
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventor: Chien-Tien Chen
  • Patent number: 10828296
    Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: November 10, 2020
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
  • Patent number: 10702576
    Abstract: The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: July 7, 2020
    Assignees: IRONWOOD PHARMACEUTICALS, INC., FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
  • Patent number: 10675325
    Abstract: The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 9, 2020
    Assignees: IRONWOOD PHARMACEUTICALS, INC., FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
  • Patent number: 10668135
    Abstract: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: June 2, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, George Hajishengallis
  • Patent number: 10660939
    Abstract: The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 26, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, John H. Dodd, Marie Makhlina
  • Patent number: 10626146
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 21, 2020
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Patent number: 10328117
    Abstract: Peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production are described.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: June 25, 2019
    Assignee: AILERON THERAPEUTICS, INC.
    Inventor: Huw M. Nash
  • Patent number: 10251932
    Abstract: The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: April 9, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Venkata-Rangarao Kanikanti, Petra Lange, Hans-Juergen Hamann, Peter Kleinebudde
  • Patent number: 10100084
    Abstract: Template-fixed ?-hairpin peptidomimetics of the general formulae wherein Z is a chain of 11 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially Cathepsin G or Elastase or Tryptase. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: October 16, 2018
    Assignees: POLYPHOR LTD., UNIVERSITAT ZURICH
    Inventors: Steven J. Demarco, Kerstin Moehle, Heiko Henze, Odile Sellier, Francoise Jung, Frank Gombert, Daniel Obrecht, Christian Ludin
  • Patent number: 10035824
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 31, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Patent number: 9700592
    Abstract: Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: July 11, 2017
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, Robert Jordan, Jeffrey D. Edelson
  • Patent number: 9675661
    Abstract: Peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production are described.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 13, 2017
    Assignee: AILERON THERAPEUTICS, INC.
    Inventor: Huw M. Nash
  • Patent number: 9220771
    Abstract: The invention relates to the use of the Peptide of the formula Cyclo-(Arg-Gly-Asp-DPhe-NMe-Val) and/or the pharmaceutically acceptable derivatives, solvates and/or salts thereof, for the manufacture of a medicament for the treatment of breast cancer and/or bone metastases in humans, wherein the medicament is optionally to be used in combination with one or more cancer cotherapeutic agents, preferably selected from a) hormone modulating agents, b) osteoclast activity modulating agents, c) cancer chemotherapeutic agents, and/or d) radiotherapy, alone, concurrently or not in the dosage regime of the present invention.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: December 29, 2015
    Assignee: MERCK PATENT GMBH
    Inventors: Anne Kerber, Tobias Baeuerle
  • Patent number: 9175056
    Abstract: Peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production are described.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: November 3, 2015
    Assignee: Alleron Therapeutics, Inc.
    Inventor: Huw M. Nash
  • Patent number: 9056076
    Abstract: The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: June 16, 2015
    Assignee: Potentia Pharmaceuticals, Inc.
    Inventors: Pascal Deschatelets, Paul Olson, Cedric Francois
  • Publication number: 20150148290
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Application
    Filed: October 31, 2014
    Publication date: May 28, 2015
    Inventors: Eric Marsault, Carl St-Louis
  • Publication number: 20150141349
    Abstract: This invention relates to methods and compositions for treating carcinoid syndrome and other adverse symptoms associated with tumor-producing neuroendocrine tumors, said methods comprising administering a therapeutically effective amount of a vascular disrupting agent, or a pharmaceutically acceptable salt thereof, to a subject having a hormone producing neuroendocrine tumor. In preferred implementations, the vascular disrupting agent is combretastatin A-4 phosphate, combretastatin A-1 diphosphate, or a pharmaceutical acceptable salt thereof.
    Type: Application
    Filed: June 21, 2013
    Publication date: May 21, 2015
    Applicant: Angiogene Pharmaceuticals Ltd.
    Inventors: Peter David Davis, David J. Chaplin
  • Publication number: 20150132237
    Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Inventors: Adelya K. Leshchiner, Nancy E. Larsen, Edward G. Parent
  • Publication number: 20150132238
    Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Inventors: Adelya K. Leshchiner, Nancy E. Larsen, Edward G. Parent
  • Publication number: 20150132375
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: January 15, 2015
    Publication date: May 14, 2015
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Patent number: 9029332
    Abstract: Cross-linked proteins and peptides, and methods of making and uses of such cross-linked proteins and peptides. The cross-linked proteins and peptides have rigid, distance-matching bismethylene aryl cross-linking moieties. Compositions comprising the cross-linked proteins and peptides can be used as pharmaceutical delivery formulations. The cross-linked proteins and peptides can have improved properties, such as cell permeability, as compared to the parent protein or peptide.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: May 12, 2015
    Assignee: The Research Foundation for The State University of New York
    Inventors: Qing Lin, Avinash Muppidi
  • Publication number: 20150126432
    Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 7, 2015
    Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Felix Galyean
  • Publication number: 20150126450
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: May 7, 2015
    Inventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian
  • Publication number: 20150126451
    Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Inventors: William D. Carlson, Peter C. Keck, Michael Sworin, Dattatreyamurty Bosukonda, Kellie Watson, Philippe Bey, Romesh Subramanian
  • Patent number: 9023258
    Abstract: A method and formulation for preparing spray dried vancomycin. In various embodiment, the formulation includes vancomycin HCl (10-20%) and one or more of the following PEG (0-5%), mannitol (0-5%), ethanol (0-10%), and a citrate buffer. Spray dried vancomycin has favorable reconstitution times and water content.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: May 5, 2015
    Assignee: Hospira, Inc.
    Inventors: Cynthia Fragale, Daniel Brueck
  • Patent number: 9023988
    Abstract: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production. Macrocycles of the invention include triazole moieties that crosslink amino acid side chains. The cross links can stabilize a secondary structure of a peptidomimetic macrocycle, such as an ?-helix.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 5, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventor: Huw M. Nash
  • Patent number: 9018172
    Abstract: Disclosed are compounds and methods relating to a chemical transformation for the conjugation of unprotected peptide biomolecules via a SNAr process between highly fluorinated aryl moieties and thiols (“fluoroaryl-thiol-click”).
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: April 28, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Bradley L. Pentelute, Alexander M. Spokoyny, Yekui Zou, Chi Zhang
  • Publication number: 20150105335
    Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventor: Richard Franklin
  • Publication number: 20150105333
    Abstract: Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-?B activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-?B activity without a second delayed increase in NF-?B activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated Massilia bacterium or population thereof capable of producing a HIV-1 reactivating factor (HRF). Also provided are methods of culturing the Massilia bacteria. Further provided are methods of reactivating a latent Human Immunodeficiency Virus-1 (HIV-1) infection in a subject comprising administering to the subject a HIV-1 reactivating factor produced by Massilia bacteria, optionally with a priming agent.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 16, 2015
    Inventors: Olaf Kutsch, Michael Niederweis, Frank Wolschendorf, Alexandra Duverger, Frederic Wagner
  • Publication number: 20150105328
    Abstract: The invention concerns peptoid-peptide hybrids that may act as protein interaction inhibitors (PPIIs). Another aspect of the invention concerns a method for treating a disorder (e.g., an oncologic disorder) in a human or animal subject, comprising administering an effective amount of a peptoid-peptide hybrid (a peptoid body) of the invention, or a composition comprising a peptoid-peptide hybrid, to the subject in need thereof. Another aspect of the subject invention concerns a method for killing or inhibiting the growth of cells (e.g., cancer cells or malaria-infected cells), comprising contacting a cancer cell in vitro or in vivo with an effective amount of a peptoid-peptide hybrid, or a composition comprising the peptoid-peptide hybrid. Another aspect of the invention concerns a method for producing a peptoid-peptide hybrid.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventors: MARK MCLAUGHLIN, PRIYESH JAIN
  • Publication number: 20150105332
    Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
    Type: Application
    Filed: May 24, 2013
    Publication date: April 16, 2015
    Applicant: CAMURUS AB
    Inventors: Catalin Nistor, Markus Johnsson, Fredrik Tiberg
  • Publication number: 20150105331
    Abstract: A high purity cyclopeptide crystal has a structure shown by Formula I. R represents H or a cation forming a pharmaceutically acceptable salt. Also disclosed are a preparation method and a use of the high-purity cyclopeptide crystal.
    Type: Application
    Filed: March 29, 2013
    Publication date: April 16, 2015
    Inventors: Shidong Liu, Zhaoli Zhang, Xiusheng Wang, Xiao Zhang, Zhijun Tang, Xiaoming Ji
  • Patent number: 9006392
    Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: April 14, 2015
    Assignee: Novacta Biosystems Limited
    Inventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
  • Publication number: 20150094272
    Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: August 17, 2012
    Publication date: April 2, 2015
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Marco Kessler, Angelika Fretzen, Hong Zhao, Robert Solinga, Vladimir Volchenok
  • Publication number: 20150094265
    Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: December 1, 2014
    Publication date: April 2, 2015
    Inventors: ANGELIKA FRETZEN, HONG ZHAO, MARCO KESSLER
  • Patent number: 8993581
    Abstract: Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: March 31, 2015
    Assignee: Trustees of Boston University
    Inventors: Susan Perrine, Douglas Faller
  • Patent number: 8992940
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: March 31, 2015
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • Publication number: 20150087597
    Abstract: Described herein are fragments of fibronectin and vitronectin and variants thereof that have certain activities, including growth factor-binding activity. Also described are fragments of growth factors that bind to fibronectin and inhibit binding of full-length growth factors to fibronectin. Compositions containing such fragments are useful in cosmetic treatments (e.g., the treatment of wrinkles or UV photodamage of skin), and the treatment of wounds and cancer.
    Type: Application
    Filed: May 1, 2014
    Publication date: March 26, 2015
    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventor: Richard A. Clark
  • Publication number: 20150080319
    Abstract: A method is provided for inhibiting TACE activity in a human subject, through the administration of a ?-defensin, analog, or derivative. Such a ?-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally. The ?-defensin, analog, or derivative can be selected to additionally inhibit ADAM-10 activity.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 19, 2015
    Inventors: Michael E. Selsted, Dat Q. Tran
  • Publication number: 20150078999
    Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1 Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
    Type: Application
    Filed: June 20, 2014
    Publication date: March 19, 2015
    Inventors: James R. Heath, Rosemary Dyane Rohde, Arundhati Nag, Samir Das, Aiko Umeda